Trial Profile

A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination With Anti-PD-1/L1 in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PTT 936 (Primary) ; B7-H1 antigen modulators; Programmed cell death 1 receptor antagonists
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Pyrotech Therapeutics

10 Aug 2026 Planned End Date changed from 28 Feb 2026 to 31 Dec 2027.
10 Aug 2026 Planned primary completion date changed from 31 Dec 2025 to 30 Sep 2027.
12 Mar 2025 Number of treatment arms have been decreased from 10 to 6 by removing the arms for Dose levels 6,7 8 and 9.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com